Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
KY1702 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
KY1702: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
KFA-115 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
KFA-115: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
TQB-3824 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
TQB-3824: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
HECB-1701301 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
HECB-1701301: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
EOS-984 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
EOS-984: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
RFUS-1646 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
RFUS-1646: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
SAR-444559 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
SAR-444559: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
XZ-120 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
XZ-120: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ET-0038 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
ET-0038: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
LMY-922 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
LMY-922: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
[89Zr]Zr-DFO-APAC Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
[89Zr]Zr-DFO-APAC: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
BR-3409 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
26 August 2026
BR-3409: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.